 NEW YORK, May 19, 2021 GLOBE NEWSWIRE -- Y-mAbs Therapeutics, Inc. the Company or Y-mAbs Nasdaq: YMAB a commercial-stage biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer announced today that it has entered into an exclusive distribution agreement with Adium Pharma S.A. Adium to be the exclusive distributor in Latin America of the Companys antibodies, DANYELZA naxitamab-gqgk for the treatment of patients with relapsedrefractory high-risk neuroblastoma and omburtamab, if approved, for the treatment of pediatric patients with CNSleptomeningeal metastasis from neuroblastoma. 